These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28277330)

  • 1. PharmGKB summary: voriconazole pathway, pharmacokinetics.
    Barbarino JM; Owusu Obeng A; Klein TE; Altman RB
    Pharmacogenet Genomics; 2017 May; 27(5):201-209. PubMed ID: 28277330
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
    Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection.
    Kennedy B; Larcombe R; Chaptini C; Gordon DL
    J Antimicrob Chemother; 2015 Jul; 70(7):2171-3. PubMed ID: 25777322
    [No Abstract]   [Full Text] [Related]  

  • 4. [The role of voriconazole in the treatment of emerging mycoses].
    Pastor FJ; Guarro J
    Rev Iberoam Micol; 2007 Sep; 24(3):228-32. PubMed ID: 17874861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
    Heyn K; Tredup A; Salvenmoser S; Müller FM
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.
    Box H; Negri C; Livermore J; Whalley S; Johnson A; McEntee L; Alastruey-Izquierdo A; Meis JF; Thornton C; Hope W
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439967
    [No Abstract]   [Full Text] [Related]  

  • 7. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
    Isham N; Ghannoum MA
    J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole: How to Use This Antifungal Agent and What to Expect.
    Malani AN; Kerr LE; Kauffman CA
    Semin Respir Crit Care Med; 2015 Oct; 36(5):786-95. PubMed ID: 26398543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro antifungal activity of voriconazole: New data after the first years of clinical experience].
    Quindós G; Carrillo-Muñoz AJ; Eraso E; Cantón E; Pemán J
    Rev Iberoam Micol; 2007 Sep; 24(3):198-208. PubMed ID: 17874856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics.
    Trubiano JA; Paratz E; Wolf M; Teh BW; Todaro M; Thursky KA; Slavin MA
    Mycoses; 2014 Sep; 57(9):572-6. PubMed ID: 24761988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro synergy of natamycin and voriconazole against clinical isolates of
    Sradhanjali S; Yein B; Sharma S; Das S
    Br J Ophthalmol; 2018 Jan; 102(1):142-145. PubMed ID: 28982951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole -- better chances for patients with invasive mycoses.
    Ghannoum MA; Kuhn DM
    Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro combination of voriconazole and miltefosine against clinically relevant molds.
    Imbert S; Palous M; Meyer I; Dannaoui E; Mazier D; Datry A; Fekkar A
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6996-8. PubMed ID: 25199776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections.
    Lewis RE
    Am J Ther; 2012 Jan; 19(1):51-63. PubMed ID: 21248618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole: therapeutic review of a new azole antifungal.
    Herbrecht R
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):485-97. PubMed ID: 15482215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scedosporium prolificans Otitis Externa.
    Wen SC; Phillips D; Gwee A
    Pediatr Infect Dis J; 2016 Nov; 35(11):1277. PubMed ID: 27753775
    [No Abstract]   [Full Text] [Related]  

  • 17. Voriconazole-refractory invasive aspergillosis.
    Park SY; Yoon JA; Kim SH
    Korean J Intern Med; 2017 Sep; 32(5):805-812. PubMed ID: 28835093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
    Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
    Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antifungal activity and clinical efficacy of liposomal amphotericin B (AmBisome)].
    Maniwa T; Yamamoto Y
    Nihon Yakurigaku Zasshi; 2007 Feb; 129(2):129-34. PubMed ID: 17299241
    [No Abstract]   [Full Text] [Related]  

  • 20. [Otomastoiditis due to Scedosporium apiospermum. Hallucinations as an adverse reaction to voriconazol].
    Fuster-Escrivá B; Chanzá-Aviñó M; Concepción Gimeno-Cardona
    Rev Iberoam Micol; 2019; 36(3):165-166. PubMed ID: 31303483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.